Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Glucose-Dependent Insulinotropic Polypeptide Augments Glucagon Responses to Hypoglycemia in Type 1 Diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in HNF1A-diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  2. Cardiac Autonomic Function is Associated With Myocardial Flow Reserve in Type 1 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Investigating Intestinal Glucagon after Roux-en-Y Gastric Bypass Surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Non-alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prognostic value of ratio of transmitral early filling velocity to early diastolic strain rate in patients with Type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The Liver-α-Cell Axis and Type 2 Diabetes

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

Glucose-dependent insulinotropic polypeptide (GIP) is glucagonotropic and glucagon-like peptide 1 (GLP-1) is glucagonostatic. We studied the effects of GIP and GLP-1 on glucagon responses to insulin-induced hypoglycemia in patients with type 1 diabetes mellitus (T1DM).Ten male subjects with T1DM (C-peptide negative, age: 26±1 years (mean±SEM); BMI: 24±0.5 kg/m(2); HbA1c 7.3±0.2%) were studied in a randomized, double-blinded, cross-over study, with 2-hour iv administration of saline, GIP or GLP-1. The first hour, plasma glucose was lowered by insulin infusion, and the second hour constituted a 'recovery phase'.During the recovery phase GIP infusions elicited larger glucagon responses (164±50 (GIP) vs. 23±25 (GLP-1) vs. 17±46 (saline) min×pmol/l, P<0.03) and endogenous glucose production was higher with GIP and lower with GLP-1 as compared to saline (P<0.02). On the GIP days significantly less exogenous glucose was needed to keep plasma glucose above 2 mmol/l (155±36 (GIP) vs. 232±40 (GLP-1) vs. 212±56 (saline) mg×kg(-1), P<0.05). Levels of insulin, cortisol, growth hormone, and noradrenaline, as well as hypoglycemic symptoms and cognitive function, were similar on all days.Our results suggest that during hypoglycemia in patients with T1DM exogenous GIP increases glucagon responses during the 'recovery phase' after hypoglycemia and reduces the need for glucose administration.

Original languageEnglish
JournalDiabetes
Volume64
Issue number1
Pages (from-to)72-78
ISSN0012-1797
DOIs
Publication statusPublished - 2015

ID: 44521771